10x Genomics: Is Now the Time to Buy?
Update: 2025-09-11
Description
10x Genomics stock saw a bump after Piper Sandler gave it a Neutral rating with a $15 price target, despite trading lower. The company, a leader in single-cell tech, has shown recent positive momentum with a strong earnings report and restructuring. However, the stock is volatile, down 10% YTD and nearly half from last year's high, making it a potentially risky investment despite renewed interest in biotech and AI.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
